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Abstract
Background: Two therapeutic options are currently avail-
able for patients with mild-to-moderate idiopathic pulmo-
nary fibrosis (IPF): pirfenidone and nintedanib. To date, there 
is still insufficient data on the efficacy of these 2 agents in 
patients with more severe disease. Objectives: This national, 
multicenter, retrospective real-life study was intended to de-
termine the impact of nintedanib on the treatment of pa-
tients with severe IPF. Methods: All patients included had 
severe IPF and had to have at least 6 months of follow-up 
before and at least 6 months of follow-up after starting nint-
edanib. The aim of the study was to compare the decline in 
lung function before and after treatment. Patient survival af-
ter 6 months of therapy with nintedanib was assessed. Re-
sults: Forty-one patients with a forced vital capacity (FVC) 
≤50% and/or a diffusing capacity of the lung for carbon 
monoxide (DLCO) ≤35% predicted at the start of nintedanib 
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treatment were enrolled. At the 6-month follow-up, the de-
cline of DLCO (both absolute and % predicted) was signifi-
cantly reduced compared to the pretreatment period (abso-
lute DLCO at the –6-month, T0, and +6-month time points 
(5.48, 4.50, and 5.03 mmol/min/kPa, respectively, p = 0.03; 
DLCO% predicted was 32.73, 26.54, and 29.23%, respectively, 
p = 0.04). No significant beneficial effect was observed in the 
other functional parameters analyzed. The 1-year survival in 
this population was 79%, calculated from month 6 of thera-
py with nintedanib. Conclusions: This nationwide multi-
center experience in patients with severe IPF shows that 
nintedanib slows down the rate of decline of absolute and % 
predicted DLCO but does not have significant impact on FVC 
or other lung parameters. © 2018 S. Karger AG, Basel
Introduction
For the treatment of idiopathic pulmonary fibrosis 
(IPF), an extremely disabling condition associated with a 
high mortality rate [1], 2 pharmaceutical agents, with 
mechanisms of action and pharmacological profiles very 
different from each other, have been on the market for 
some years now. Italian epidemiological data report a 
variable incidence and prevalence of IPF: between 2.3 and 
5.3 cases per 100,000 person-years and between 12.6 and 
35.5 cases per 100,000 person-years, respectively, de-
pending on the criteria adopted for disease definition, 
with an average survival of 3.7 years from diagnosis [2].
The efficacy of the 2 agents in patients with mild-to-
moderate IPF (as assessed by functional impairment) was 
proven by prospective multicenter randomized con-
trolled studies [3–6] as well as in several real-life studies 
[7–12]. However, much less data are available on the ef-
ficacy of these new therapeutic options in patients with 
more advanced stages of the disease [13–15].
Nintedanib became available in Italy as well as in oth-
er European countries after the marketing of pirfenidone 
and following a compassionate use program (named pa-
tient use [NPU]). This program made the treatment avail-
able for subjects who were not eligible for pirfenidone 
therapy or who had suffered side effects from pirfeni-
done. Thus, the vast majority of patients admitted to the 
NPU program were affected by severe IPF, since only 
those with mild-to-moderate functional impairment 
were eligible for pirfenidone treatment. With this back-
ground, we collected data on such patients from all Italian 
reference centers for the diagnosis and treatment of IPF 
that had included at least 5 patients into the nintedanib 
NPU program. The aim of the study was to assess the 
trend of lung function parameters in this subset of highly 
selected patients.
Materials and Methods
Study Design and Methods
In November 2014, Boehringer Ingelheim Inc. supported an 
NPU program that introduced nintedanib as a treatment for pa-
tients with IPF in Italy. In order to enter the study, patients had to 
be over 40 years of age and with a confirmed diagnosis of IPF in 
accordance with the international guidelines [1]. Subjects who 
were not eligible for the treatment with pirfenidone due to poor 
functional parameters (forced vital capacity [FVC] ≤50% and/or 
diffusing capacity of the lung for carbon monoxide [DLCO] ≤35%) 
or those who had experienced intolerable side effects from the drug 
were included in the NPU program. Of the latter, only patients 
who met the severity functional criteria required by our study 
(FVC ≤50% predicted and/or DLCO ≤35% predicted) were includ-
ed in our series. Patients with an FVC > 50% could be also enrolled 
if they were unable to undergo DLCO testing, considering these pa-
tients with a severe disease. These patients had to have gone 
through a 6-month (SD ±2) follow-up period before starting nin-
tedanib followed by a further follow-up period of at least 6 months 
(SD ±2) after starting treatment. A 6-month pretreatment period 
was believed to represent the minimum length of time to assess 
disease behavior in terms of lung function. Similarly, we consid-
ered 6 months to be the minimal period to evaluate response to the 
treatment. 
Exclusion criteria for the NPU program included alanine ami-
notransferase, aspartate aminotransferase or bilirubin levels high-
er than 1.5 times the upper limit of normal; bleeding risk or throm-
bosis; planned major surgery within the next 3 months, including 
lung transplantation, major abdominal, or major intestinal sur-
gery; myocardial infarction within the previous 6 months, or un-
stable angina within the last month. All patients were assessed for 
eligibility to the study through a centralized review supported by 
the sponsor. All patients gave their written informed consent, and 
approval by the ethics committee was obtained. The NPU program 
was closed in April 2016 when nintedanib became available on the 
Italian market for the treatment of IPF. We therefore asked all Ital-
ian reference centers for the diagnosis and treatment of IPF that 
had included at least 5 patients into the nintedanib NPU program 
to send us the files of the patients with a diagnosis of IPF estab-
lished according to the 2011 international guidelines [1]. This was 
a spontaneous and unsponsored study. The coordinator center, 
San Giuseppe Hospital, Milan, obtained the authorization by its 
Ethics Committee (No. 285/2016). In compliance with the Italian 
regulations, the participating centers did or tried to acquire in-
formed consent from the enrolled patients, since this was a retro-
spective trial. When informed consent was not possible to obtain 
due to death of the subject or his/her unavailability, track of the 
acquisition attempt was kept by the reference center.
The primary aim of the study was to evaluate the trend of lung 
function parameters before and after nintedanib treatment and to 
detect a possible change in the trend of the functional decline. No-
tably, we intended to assess whether the functional deterioration 
(in terms of % predicted and/or absolute loss of FVC and DLCO) 
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could be modified by nintedanib. Survival of patients after the 
6-month treatment period with nintedanib, which was determined 
through September 30, 2016, was also recorded.
Statistical Analysis
Lung function measurements were taken at 6 months (SD ±2) 
before starting treatment with nintedanib (T–1), at the time of the 
first nintedanib intake (T0), and at 6 months (SD ±2) after the start 
of nintedanib therapy (T1). Changes in lung function parameters 
during the pretreatment (T0–T–1) and posttreatment (T1–T0) pe-
riods were then calculated.
The differences between post- and pretreatment modifications 
in lung function parameters were tested with the Wilcoxon signed-
rank test. In addition, the correlation between these differences 
was evaluated using the Spearman rank correlation coefficient.
All patients were followed up after T1 (6 months after the ini-
tiation of nintedanib therapy). Vital status was determined by each 
participating center until September 30, 2016. The overall survival 
observed in the cohort was estimated using the Kaplan-Meier 
method. p values < 0.05 were considered statistically significant.
The statistical analysis was performed using STATA 11 (Stata-
Corp 2009 Stata Statistical Software Release 11; StataCorp LP, Col-
lege Station, TX, USA).
Results
Forty-one patients from 9 Italian centers were enrolled 
in the study. Table 1 shows the number of subjects in-
cluded by each participating center. The mean age of the 
participants was 70 years (±SD 8) with a marked preva-
lence of males (83%). The mean time from diagnosis was 
20 months (±SD 28). Only 7 subjects had been previous-
ly treated with pirfenidone, while the majority (59%) had 
received low-dose steroids. Histological diagnosis was 
available only in 6 patients (15%).
Figure 1 and Table 2 show the study results. The de-
cline of both absolute DLCO and DLCO% predicted was 
positively and significantly influenced by the introduc-
tion of nintedanib (absolute DLCO was 5.48 mmol/min/
kPa at T–1, 4.50 at T0, and 5.03 at T1, p = 0.03; DLCO% pre-
dicted was 32.73% at T–1, 26.4% at T0, and 29.23 T–1, p = 
0.04). No significant modifications were observed in the 
other parameters analyzed (FVC, forced expiratory vol-
ume in 1 second [FEV1], total lung capacity [TLC], and 
FVC%/DLCO%). Since not all subjects were able to per-
form a 6-min walk test, the data available was insufficient 
to conduct a meaningful statistical analysis. Differences 
in changes between the post- and pretreatment values for 
DLCO% and FVC% were positively and significantly cor-
related (rho = 0.48, p = 0.02). 
Two patients were excluded from the survival analysis 
because their follow-up data after the first 6 months of 
nintedanib treatment was unavailable. The median dura-
tion of the follow-up time was 7 months (range 2–16). A 
total of 6 deaths occurred during follow-up. The survival 
probability at 12 months was 79% (95% CI: 58–91%) 
(Fig. 2).
Table 1. Patient characteristics (N = 41) at baseline (T0, first nint-
edanib intake)
Center
Ancona 3 (7)
Catania 3 (7)
Foggia 2 (5)
Forlì 5 (12)
Milan 7 (17)
Modena 2 (5)
Monza 4 (10)
Padua 2 (5)
Rome 5 (12)
Siena 6 (15)
Trieste 2 (5)
Gender
Female 7 (17)
Male 34 (83)
Agea
55–64 years 7 (17)
65–74 years 20 (49)
75+ years 14 (34)
Smoking status
Ex-smoker 28 (68)
Nonsmoker 11 (27)
Smoker 2 (5)
Histological diagnosis
No 35 (85)
Yes 6 (15)
Clinical/radiological diagnosis
Definite UIP 26 (63)
Possible UIP 15 (37)
Corticosteroids
No 17 (41)
Yes 24 (59)
Pirfenidone
No 34 (82.9)
Yes 7 (17.1)
N-Acetylcysteine
No 36 (88)
Yes 5 (12)
Time from diagnosisb
0–5 months 11 (27)
6–11 months 12 (29)
>12 months 18 (44)
Values are n (%). a Mean age 70 ± 8 years. b Mean time from 
diagnosis 20 ± 28 months. UIP, usual interstitial pneumonia.
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Fig. 1. Changes in the spirometry parameters evaluated at 6 months 
before starting treatment with nintedanib (T–1), at the time of the 
first nintedanib intake (T0) and at 6 months after the initiation of 
nintedanib therapy (T1). FVC, forced vital capacity; DLCO, diffus-
ing capacity of the lung for carbon monoxide; FEV1, forced expira-
tory volume in 1 second; TLC, total lung capacity.
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Fig. 2. Survival probability for patients fol-
lowed up after 6 months of nintedanib 
treatment (n = 39).
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Discussion
To our knowledge, this is the first study that evaluated 
the effectiveness of nintedanib treatment in a patient pop-
ulation with severe IPF. Such a population has generally 
been excluded from randomized controlled trials. Our 
study has the typical pros and cons of real-life studies al-
ready discussed in previous papers [14, 16]. It is at the 
same time a national multicenter retrospective analysis 
truly representative of the real situation of patients af-
fected by a more severe form of IPF.
Our study population had the same characteristics as 
those in other studies. In particular, it was very similar to 
a patient series described in one of our previous investiga-
tions on pirfenidone [14]. In our previous study, 75% of 
the enrolled patients were male (83% in the present 
study), 79% had a history of smoking (73% in the present 
study), and the mean age was 69 years (70 in this study). 
The only difference worth mentioning is the percentage 
of histological diagnoses. In our previous work, 25% of 
the enrolled subjects had undergone lung biopsy versus 
only 15% in the present series. This is probably due to an 
even greater disease severity and the risks related to an 
invasive diagnostic procedure unlikely to significantly 
change disease management, as these patients would be 
denied antifibrotic therapies due to their functional con-
ditions, until the introduction of the NPU program. Most 
patients with severe IPF enrolled in the present study had 
Table 2. Changes in lung function parameters at T–1, T0, and T1
Parameter N Time Mean (SD) Changes (95% CI) Difference 
in changes (SD)
p value
FVC, L 39 T–1 2.05 (0.58) – –
39 T0 1.99 (0.54) –0.07 (–0.15; 0.02) –
39 T1 1.87 (0.58) –0.12 (–0.20; –0.04) –0.06 (0.36) 0.22
FVC% 41 T–1 61.83 (15.25) –
41 T0 60.63 (14.57) –1.20 (–3.78; 1.39)
41 T1 58.00 (17.77) –2.63 (–5.21; –0.06) –1.44 (12.36) 0.34
DLCO, mmol/min/kPa 22 T–1 5.48 (3.25) –
22 T0 4.50 (2.77) –0.98 (–1.60; –0.37)
22 T1 5.03 (3.64) 0.53 (–0.47; 1.53) 1.51 (3.46) 0.03
DLCO% 26 T–1 32.73 (8.56) –
26 T0 26.54 (5.70) –6.19 (–9.26; –3.12)
26 T1 29.23 (12.08) 2.69 (–1.54; 6.93) 8.88 (15.30) 0.004
FEV1, L 37 T–1 1.72 (0.45) –
37 T0 1.70 (0.46) –0.02 (–0.10; 0.05)
37 T1 1.60 (0.44) –0.11 (–0.18; –0.03) –0.08 (0.38) 0.15
FEV1% 39 T–1 67.62 (16.02) –
39 T0 66.67 (15.62) –0.95 (–4.43; 2.53)
39 T1 63.62 (17.66) –3.05 (–5.64; –0.46) –2.10 (15.62) 0.37
TLC, L 15 T–1 3.85 (1.13) –
15 T0 3.78 (1.03) –0.07 (–0.34; 0.20)
15 T1 3.73 (1.01) –0.05 (–0.48; 0.38) –0.02 (1.07) 1
TLC% 17 T–1 59.06 (13.73) –
17 T0 58.71 (13.46) –0.35 (–4.34; 3.64)
17 T1 57.65 (13.16) –1.06 (–6.60; 4.48) –0.71 (15.74) 0.83
FVC%/DLCO% 26 T–1 2.17 (0.79) – –
26 T0 2.60 (0.97) 0.43 (0.20; 0.66) –
26 T1 2.87 (2.42) 0.27 (–0.55; 1.10) 0.15 (2.29) 0.73
FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; 
TLC, total lung capacity.
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previously received low doses of steroids (59%) as it is 
commonly the case in clinical practice. Only 8% had re-
ceived N-acetylcysteine and none had received azathio-
prine, which reflects the good adherence to the interna-
tional and Italian treatment guidelines of the reference 
centers [1, 17]. Only a few patients (7 subjects, 17% of the 
overall study population) had been formerly treated with 
pirfenidone, which was then discontinued because of side 
effects. Such a small number of individuals is unlikely to 
have substantially affected the trend in lung function be-
fore the beginning of nintedanib treatment. Previous 
treatment with low-dose steroids and subsequent taper-
ing (not performed in all patients) should not have had 
an impact on the functional behavior of our population. 
The study population was too small to perform any anal-
ysis of these aspects. It was a homogeneous group of pa-
tients with a definitive or possible diagnosis of usual in-
terstitial pneumonia.
The positive effect of nintedanib on the decline of ab-
solute and DLCO% predicted was not paralleled by a simi-
lar effect on either FVC or other parameters; however, 
differences in changes between post- and pretreatment 
for DLCO% predicted and FVC% predicted were positive-
ly and significantly correlated. This could be due to sev-
eral reasons. A first hypothesis could be that the effect on 
DLCO foreshadows that on the FVC trend. This happens 
in other disorders such as lymphangioleiomyomatosis 
[18, 19] and could probably be identified by examining 
the data after a longer follow-up time. However, the se-
verity of the patients’ condition and their high risk of 
mortality led us to measure the trend before and after 6 
months of treatment only, considering this period of time 
to be long enough to verify the level of exposure to the 
drug or to observe and record the trajectory of the disease. 
The effects on DLCO may be driven by some outliers with 
significant improvement, as seen in Figure 1; however, 
the data still remain significant without considering 
those. Finally, we preferred to keep all subjects in the data 
set using a method that is also robust for the presence of 
outliers. It should also be noted that only 26 out of 41 pa-
tients were able to undergo the 3 pre-specified periodic 
determinations of DLCO. In other words, we observed a 
positive trend in about half of our total sample, while ap-
proximately 40% of the patients were unable to tolerate 
the test at any time in the course of the study, indicating 
a more severe stage of disease. We hence believe that our 
data on nintedanib-induced change in DLCO should be 
interpreted with caution and evaluated more rigorously 
in future studies.
A further possible explanation is that the drug given to 
subjects so heavily compromised has sometimes been ad-
ministered to cases too severely ill to produce a significant 
benefit. The high mortality at 12 months (21%) is coun-
terevidence of this. A severity subgroup analysis of pa-
tients enrolled in the INPULSIS trials has suggested that 
the drug effect is identical in the different subsets of pa-
tients stratified based on FVC value and GAP index [20, 
21]. This was not confirmed in our group of severely com-
promised patients. Reassuringly, however, we observed 
that patients with a more favorable trend in DLCO% varia-
tion were also those with a more favorable trend in FVC%. 
It is possible that a larger patient population followed for 
a longer time could have uncovered positive results also 
with respect to FVC. It is equally likely that nintedanib 
had an effect on pulmonary hypertension generally asso-
ciated with the advanced stages of IPF [22] as it happens 
with other tyrosine kinases inhibitors in subjects with 
pulmonary arterial hypertension [23]. However, this is 
only an entirely speculative hypothesis since no data sup-
port it (echocardiographic data provided by the partici-
pating centers were unfortunately too limited to allow a 
precise estimation; yet, no significant variation in FVC%/
DLCO% was observed). A review article by Meltzer and 
Noble [24] suggests that DLCO strongly correlates with 
pulmonary hypertension and that there is a negative cor-
relation between them. In a randomized placebo-con-
trolled trial on imatinib in IPF over 96 weeks, DLCO was a 
secondary end point that at all different time points of 
observation did not change in the experimental arm com-
pared to the control group [25]. Our study is therefore the 
first to report a possible improvement in lung diffusion 
capacity following treatment with an antifibrotic medica-
tion specific to IPF.
These data are important because they highlight that 1 
of the 2 antifibrotic drugs currently available for the treat-
ment of IPF may also be effective in the more advanced 
stages of the disease. The mechanism of action that influ-
ences the variations of absolute and DLCO% in this series 
still needs to be explored, but the trend gives an important 
and positive signal. The lung diffusion capacity is indeed 
considered, together with FVC, as one of the most impor-
tant prognostic factors for IPF [26–31]. This result is even 
more significant given that it was recorded in a real-life 
study that more closely reflects the real complexity of sick 
patients than the selected populations in clinical trials do.
Our work has many limitations. It is a retrospective 
study, and the number of patients is limited, although the 
cohort studied here summarizes the defining features of 
typical patients well. Due to the characteristics of the sub-
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jects and the severity of their disease, it was not possible 
to collect data about other important parameters that 
would otherwise have enabled a more detailed interpreta-
tion of our findings. These include the 6-min walk test 
(only a few patients performed it and an even smaller pro-
portion of them had serial tests due to the severity of their 
condition) and an echocardiographic study for the detec-
tion of a possible associated pulmonary hypertension. Pa-
tients who had to discontinue therapy for any reasons in-
cluding side effects and toxicities during the first 6 months 
of treatment were not included in our study, and there-
fore, it was not possible to analyze these data. Finally, our 
results might also be interpreted as a negative study due 
to the absence of effect of nintedanib on the trend of FVC; 
however, for the reasons discussed above, this is not our 
interpretation. The difference in trend between absolute 
and DLCO% values on the one hand and FVC on the oth-
er hand needs to be further investigated in prospective 
studies involving a larger population of patients. Despite 
these limitations, which are common to studies of this 
kind, we believe that the final message of this work is in-
teresting. It in fact opens up venues for the evaluation of 
nintedanib even in the most severely sick patients who are 
today orphans of any treatment, have a very poor prog-
nosis, and await therapeutic answers beyond palliation. 
In addition, therapies able to slow down the course of the 
disease, even in its most advanced stages, could be a 
bridge to lung transplantation. In conclusion, this nation-
wide multicenter experience in patients with severe IPF 
shows that nintedanib slows down the rate of decline of 
absolute and % predicted DLCO but does not have a sig-
nificant impact on the decline of FVC or other lung func-
tion parameters.
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